Leerink Partnrs Issues Optimistic Forecast for CSTL Earnings

Castle Biosciences, Inc. (NASDAQ:CSTL) – Equities researchers at Leerink Partnrs boosted their FY2025 earnings estimates for shares of Castle Biosciences in a research report issued on Monday, November 3rd. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.23) per share for the year, up from their prior estimate of ($0.64). The consensus estimate for Castle Biosciences’ current full-year earnings is $0.44 per share. Leerink Partnrs also issued estimates for Castle Biosciences’ Q4 2025 earnings at ($0.17) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.42) EPS and FY2027 earnings at ($0.76) EPS.

A number of other brokerages also recently commented on CSTL. Robert W. Baird boosted their target price on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a report on Tuesday. Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 10th. BTIG Research raised their target price on Castle Biosciences from $32.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday. Zacks Research upgraded Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Castle Biosciences in a research note on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.43.

Castle Biosciences Price Performance

NASDAQ CSTL opened at $33.57 on Thursday. The stock has a market cap of $979.91 million, a price-to-earnings ratio of -74.60 and a beta of 1.12. The company has a current ratio of 6.47, a quick ratio of 6.69 and a debt-to-equity ratio of 0.02. Castle Biosciences has a 12 month low of $14.59 and a 12 month high of $34.64. The company’s 50 day moving average is $23.68 and its two-hundred day moving average is $20.26.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The business had revenue of $83.04 million for the quarter, compared to analyst estimates of $71.06 million. Castle Biosciences has set its FY 2025 guidance at EPS.

Insider Buying and Selling

In other Castle Biosciences news, COO Kristen M. Oelschlager sold 12,678 shares of the firm’s stock in a transaction that occurred on Friday, October 31st. The stock was sold at an average price of $25.04, for a total transaction of $317,457.12. Following the completion of the sale, the chief operating officer owned 27,569 shares in the company, valued at $690,327.76. This trade represents a 31.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Derek J. Maetzold sold 1,339 shares of Castle Biosciences stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $22.44, for a total value of $30,047.16. Following the completion of the transaction, the insider owned 62,988 shares of the company’s stock, valued at approximately $1,413,450.72. The trade was a 2.08% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 15,356 shares of company stock valued at $376,922. 6.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Castle Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Castle Biosciences by 11.7% during the first quarter. Vanguard Group Inc. now owns 2,047,565 shares of the company’s stock worth $40,992,000 after purchasing an additional 215,030 shares during the period. Principal Financial Group Inc. raised its position in shares of Castle Biosciences by 2.2% during the first quarter. Principal Financial Group Inc. now owns 1,467,873 shares of the company’s stock worth $29,387,000 after purchasing an additional 32,208 shares during the period. Wasatch Advisors LP raised its position in shares of Castle Biosciences by 5.1% during the second quarter. Wasatch Advisors LP now owns 1,049,773 shares of the company’s stock worth $21,436,000 after purchasing an additional 51,318 shares during the period. Wellington Management Group LLP raised its position in shares of Castle Biosciences by 14.7% during the first quarter. Wellington Management Group LLP now owns 828,528 shares of the company’s stock worth $16,587,000 after purchasing an additional 106,408 shares during the period. Finally, Braidwell LP raised its position in shares of Castle Biosciences by 125.3% during the second quarter. Braidwell LP now owns 822,735 shares of the company’s stock worth $16,800,000 after purchasing an additional 457,488 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.